What we’ve witnessed in 2017 are simply “tips of the iceberg.” More good news should come in the oncology space (especially CAR-T).Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Hung Tran, MD, MS, CNPR, (in collaborations with Dr.The randomized, double-blind, placebo controlled, phase 3 study, Keynote-189 investigated the efficacy and safety of pembrolizumab (Keytruda) - an anti-PD-1 immunotherapy - used in combinations with either carboplatin or cisplatin in 614 patients with metastatic NSCLC.
This new trend in GPCR drug discovery requires us to understand the structural and molecular mechanisms of β-arrestin-biased agonism, which largely remain unclear.
Equally important is that today the firm announced the positive outcomes for phase 3 trial coined Keynote-189.
The aforesaid study investigated the flagship product, Keytruda (in combination with either cisplatin or carboplatin) for the 1st-line management of non-small cell lung cancer (“NSCLC”).
Data results observed thus far for CAR-T are highly promising.
CAR-Ts can cure highly resistant cancers with stellar outcomes.